Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cantharidin - Verrica Pharmaceuticals

Next Previous
Drug Profile

Cantharidin - Verrica Pharmaceuticals

Alternative Names: Cantharidin 0.7% topical solution; TO-208; VP 102 - Verrica Pharmaceuticals; VP 103; VP 103 - Verrica Pharmaceuticals; VP-102; YCANTH

Latest Information Update: 25 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verrica Pharmaceuticals
  • Developer Torii Pharmaceutical; Verrica Pharmaceuticals
  • Class Antivirals; Benzofurans; Epoxy compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Serine protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Molluscum contagiosum
  • Phase II Genital warts; Warts

Most Recent Events

  • 24 Apr 2024 Verrica Pharmaceuticals has multiple patents issued for Cantharidin in USA, Australia, Brazil, Canada, India, Israel, Japan, South Korea, Mexico, Australia, China, Europe
  • 26 Mar 2024 The US FDA granted New Chemical Entity (“NCE”) Status to the cantharidin
  • 26 Mar 2024 The US FDA listed cantharidin in the Orange Book
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top